Its benefit was first observed in the Asian phase-II DESTINY-Gastric01 trial in pretreated HER2-positive advanced GC patients, while the control group received CHT (median OS 12.5 vs. 8.4 months, HR 0.59, 95% CI 0.39–0.88, p = 0.01) [39]. This evidence concerns the gene ERBB2 and gastric cancer.